Clinical Trial Update: Study of Olverembatinib (HQP1351) in Patients With CP-CML [Phase 3]

View source ↗

Summary

This report notes a Phase 3 clinical trial evaluating Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Chronic Myeloid Leukemia, CML | Phase 3 | Status: RECRUITING